novel coronavirus pneumonia (COVID-19)
Conditions
Interventions
Control group:Keep ritonavir/ritonavir treatment
Experimental group:Favipiravir
Sponsors
The Third People's Hospital of Shenzhen
Eligibility
Sex/Gender
All
Age
16 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. 16 to 75 years of age, male or female; 2. Respiratory or blood samples tested positive for novel coronavirus; 3. A novel coronavirus nucleic acid was detected in respiratory or anal swabs after 10 days of standard treatment with roranavir / ritonavir; 4. Willing to take contraception during the study and within 7 days after treatment; 5. No difficulty in swallowing the Pills; 6. Willing to sign informed consent form.
Exclusion criteria
Exclusion criteria: 1. Any situation which the protocol cannot be carried out safely; 2. Patient refuses to receive invasive tracheal support (if needed); 3. Pregnant or lactating women:childbearing age women with positive pregnancy test, breastfeeding, miscarriage or within 2 weeks after delivery.Postmenopausal and hysterectomy women do not need a pregnancy test; 4. Patients with chronic liver and kidney disease and reaching end-stage; 5. Previous history of allergic reactions to Fapiravir or Lopinavir and Ritonavir; 6. After the investigator's judgment, the subjects could not participate the study protocol, follow-up or self-evaluation after enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood routine tests, Liver function examination, Renal function examination, Blood gas analysis, Chest CT examination; | — |
Contacts
Public ContactLiu Yingxia
Shenzhen the 3rd People's Hospital
Outcome results
None listed